Johnson & Johnson will launch its first-in-class interleukin-23 inhibitor Tremfya (guselkumab) at a premium price that is nonetheless competitive with other new biologic entrants for moderate-to-sever plaque psoriasis. The company announced the FDA approval of Tremfya July 13, with plans to launch the drug within two weeks.
Tremfya will join a crowded market for psoriasis drugs, one that has grown even more so in the last two...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?